UnknownPhase 2

Efficacy and Safety of Romiplostim Versus Eltrombopag in the Treatment of Thrombocytopenia in Patients With Wiskott-Aldrich Syndrome

Russia30 participantsStarted 2019-11-05

Plain-language summary

This is a prospective, open-label, randomized, two-arm clinical trial conducted to evaluate the safety and efficacy of romiplostim in comparison with eltrombopag in the treatment of thrombocytopenia in patients with Wiskott-Aldrich syndrome

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. abnormal hepatic function -elevated AST/ALT \> 1.5 times upper limit of normal within 4 weeks prior to enrollment
✕. Active colitis

What they're measuring

Percentage of patients with overall platelet response (complete response + partial response) for romiplostim and eltrombopag group

Timeframe: 1 month (30 day +/- 7 days)

Trial details

NCT IDNCT04371939

SponsorFederal Research Institute of Pediatric Hematology, Oncology and Immunology

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-12

Contact for this trial

Anna Shcherbina, MD, PhD

+7(495)2876570 shcher26@hotmail.com

View on ClinicalTrials.gov More Wiskott-Aldrich Syndrome trials